Probably Genetic Secures $10M ARPA-H Grant to Combat Rare Disease Delays
A rare disease patient currently faces an average five-to-seven-year diagnostic odyssey, a process often hindered by fragmented medical records. To bridge this gap, San Francisco-based Probably Genetic has secured up to $10 million from ARPA-H, aiming to deploy AI-driven diagnostic tools that synthesize patient-reported data with biological insights.
The funding, awarded under ARPA-H's Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program, empowers the company to scale its patient-centric platform. By aggregating self-reported symptoms, clinical records, and genetic data, the firm intends to build the largest AI-ready dataset for rare diseases in history. This resource is designed to bypass the limitations of traditional electronic health records, which often lack the granular detail required to identify complex phenotypic patterns.
Lukas Lange, CEO of Probably Genetic, views the initiative as a catalyst for precision medicine, likening the potential impact to transformative technologies like autonomous vehicles. The project aims to provide drug developers with the necessary evidence to identify novel targets and streamline clinical trial design. Currently, the company has already processed data from over 120,000 patients and maintains partnerships with more than 50 advocacy groups. Scott Gorman, RAPID Program Manager at ARPA-H, noted that the collaboration seeks to enable cross-disease detection at a speed and scale previously unattainable in clinical settings.
Comments (0)
No comments yet. Be the first!